BITRF.US Biotron Limited

Healthcare Biotechnology USA Stocks
0.0028 USD
Close of Nov 14, 2026
0.0011 0.0415
Market cap
USD 7.80M
P/E
-
P/B
3.89x
ROE
-52.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is BITRF.US undervalued?

Graham number

The Graham number of Biotron Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biotron Limited fundamental analysis

No fundamental analysis for Biotron Limited yet.

Biotron Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biotron Limited

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. Th…

Full company profile